Longevity Next

Regulation

Consumer Biomarker Claims Watch

Source-reviewed Last reviewed: 2026-07-06
LN Evidence Score 0 of 5
LN Claim Risk Score 3 of 5
LN Commercial Maturity Score 2 of 5
LN Clinic Transparency Score 0 of 5

Summary

Regulatory watch for consumer biomarker and direct-to-consumer test claim-risk context. The source packet maps this topic to FTC health-product advertising guidance and FDA direct-to-consumer, IVD, and laboratory-developed-test regulatory pages.

Intelligence Take

Use as a claim-risk guardrail, not as biological evidence or legal advice. The record should keep biomarker marketing language tied to substantiation, device/test context, and current regulator guidance without reaching product-specific legal conclusions.

Evidence Basis

Source packet maps this record to FTC health-product compliance guidance and FDA pages on direct-to-consumer tests, IVD regulation, and laboratory-developed tests. Evidence stage: regulator guidance and policy context; not biological efficacy evidence and not a product-specific enforcement decision.

Limitations

Not legal advice and not a finding about any specific company, test, product, or lab. Regulatory treatment can depend on test type, risk classification, jurisdiction, claims, and current agency policy. Recheck the linked FDA/FTC pages before production publication or specific product analysis.

Source-reviewed. This record summarizes regulator-source context for public claim-risk review. It is not legal advice or a product-specific regulatory conclusion.